{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:43Z","timestamp":1793361283962,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) requires intensive immunosuppressive therapy, but continued treatment beyond remission risks serious harm. Because reliable biomarkers of remission are lacking, clinicians often prolong cost-intensive and toxic therapy unnecessarily. Here, we explore the plasma proteome to identify reliable biomarkers of disease remission in patients with AAV, adjusting for patient characteristics and clinical variables. Applying a two-tiered proteomics strategy that combines global discovery with targeted validation, we identify a protein signature of remission. We then implement the resulting 7-protein panel in a targeted mass spectrometry-based assay and confirm its diagnostic performance in an independent patient cohort. The panel consistently outperforms routine markers such as C-reactive protein and ANCA titer. Our findings suggest that this 7-protein panel provides a starting point for developing a clinical tool to support decision-making, with the potential to reduce treatment-related burden, mitigate toxicity, and lower healthcare costs. More broadly, our confounder-controlled proteomics approach provides a scalable blueprint for biomarker discovery in complex inflammatory diseases.<\/jats:p>","DOI":"10.1038\/s41467-026-75755-6","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:55:37Z","timestamp":1784642137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission"],"prefix":"10.1038","volume":"17","author":[{"given":"Uwe","family":"Jerke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-534X","authenticated-orcid":false,"given":"Marieluise","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theda UP","family":"Bartolomaeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7894-6187","authenticated-orcid":false,"given":"Lovis","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojtech","family":"Kratky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-365X","authenticated-orcid":false,"given":"Zdenka","family":"Hruskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0689","authenticated-orcid":false,"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-0920","authenticated-orcid":false,"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6379","authenticated-orcid":false,"given":"Adrian","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-6993","authenticated-orcid":false,"given":"Sofia","family":"Forslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-528X","authenticated-orcid":false,"given":"Philipp","family":"Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-6718","authenticated-orcid":false,"given":"Ralph","family":"Kettritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"75755_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","volume":"403","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler, A., Bajema, I. M., Bruchfeld, A., Mastroianni Kirsztajn, G. & Stone, J. H. Diagnosis and management of ANCA-associated vasculitis. Lancet 403, 683\u2013698 (2024).","journal-title":"Lancet"},{"key":"75755_CR2","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/S2665-9913(24)00025-0","volume":"6","author":"S Arnold","year":"2024","unstructured":"Arnold, S. et al. Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitis. Lancet Rheumatol. 6, e300\u2013e313 (2024).","journal-title":"Lancet Rheumatol."},{"key":"75755_CR3","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S2665-9913(24)00035-3","volume":"6","author":"SD Falde","year":"2024","unstructured":"Falde, S. D. et al. Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis. Lancet Rheumatol. 6, e314\u2013e327 (2024).","journal-title":"Lancet Rheumatol."},{"key":"75755_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung, S. A. et al. 2021 American College of Rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 73, 1366\u20131383 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"75755_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich, B. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 83, 30\u201347 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"75755_CR6","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes, A. V. W. G KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 105, S71\u2013S116 (2024).","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"75755_CR7","doi-asserted-by":"publisher","first-page":"i171","DOI":"10.1093\/ndt\/gfv045","volume":"30","author":"JG McGregor","year":"2015","unstructured":"McGregor, J. G. et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol. Dial. Transpl. 30, i171\u2013i181 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"75755_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"75755_CR9","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3899\/jrheum.150479","volume":"42","author":"K Raimundo","year":"2015","unstructured":"Raimundo, K., Farr, A. M., Kim, G. & Duna, G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J. Rheumatol. 42, 2383\u20132391 (2015).","journal-title":"J. Rheumatol."},{"key":"75755_CR10","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1007\/s12325-023-02681-0","volume":"40","author":"L Degli Esposti","year":"2023","unstructured":"Degli Esposti, L. et al. Profile, healthcare resource consumption and related costs in ANCA-associated vasculitis patients: a real-world analysis in Italy. Adv. Ther. 40, 5338\u20135353 (2023).","journal-title":"Adv. Ther."},{"key":"75755_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036\u20131043 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"75755_CR12","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/rheumatology\/kez589","volume":"59","author":"ZS Wallace","year":"2020","unstructured":"Wallace, Z. S. et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatol. (Oxf.) 59, 2308\u20132315 (2020).","journal-title":"Rheumatol. (Oxf.)"},{"key":"75755_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","volume":"38","author":"B Sanchez Alamo","year":"2023","unstructured":"Sanchez Alamo, B. et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol. Dial. Transpl. 38, 1655\u20131665 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"75755_CR14","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","volume":"25","author":"D Furman","year":"2019","unstructured":"Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med 25, 1822\u20131832 (2019).","journal-title":"Nat. Med"},{"key":"75755_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tem.2016.09.005","volume":"28","author":"C Franceschi","year":"2017","unstructured":"Franceschi, C., Garagnani, P., Vitale, G., Capri, M. & Salvioli, S. Inflammaging and \u2018Garb-aging. Trends Endocrinol. Metab. 28, 199\u2013212 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"75755_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G., Grayson, P. C., Mahr, A. D., Lavalley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatol. (Oxf.) 51, 100\u2013109 (2012).","journal-title":"Rheumatol. (Oxf.)"},{"key":"75755_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna, M. J. et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J. Am. Soc. Nephrol. 26, 537\u2013542 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"75755_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.2014080817","volume":"26","author":"U Specks","year":"2015","unstructured":"Specks, U. Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail. J. Am. Soc. Nephrol. 26, 505\u2013507 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"75755_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"ME McClure","year":"2019","unstructured":"McClure, M. E. et al. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. J. Clin. Rheumatol. 25, 217\u2013223 (2019).","journal-title":"J. Clin. Rheumatol."},{"key":"75755_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura, M. et al. Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement. Clin. J. Am. Soc. Nephrol. 18, 47\u201359 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"75755_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","volume":"54","author":"F Alberici","year":"2015","unstructured":"Alberici, F. et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatol. (Oxf.) 54, 1153\u20131160 (2015).","journal-title":"Rheumatol. (Oxf.)"},{"key":"75755_CR22","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3899\/jrheum.100302","volume":"37","author":"AI Kalsch","year":"2010","unstructured":"Kalsch, A. I. et al. Use of highly sensitive C-reactive protein for followup of Wegener\u2019s granulomatosis. J. Rheumatol. 37, 2319\u20132325 (2010).","journal-title":"J. Rheumatol."},{"key":"75755_CR23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJMc2302460","volume":"388","author":"A Mantovani","year":"2023","unstructured":"Mantovani, A. & Garlanda, C. Humoral innate immunity and acute-phase proteins. Reply. N. Engl. J. Med 388, 1725\u20131726 (2023).","journal-title":"Reply. N. Engl. J. Med"},{"key":"75755_CR24","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.3389\/fimmu.2020.02053","volume":"11","author":"GE Thompson","year":"2020","unstructured":"Thompson, G. E. et al. Clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3 in ANCA-associated vasculitis. Front Immunol. 11, 2053 (2020).","journal-title":"Front Immunol."},{"key":"75755_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1681\/ASN.0000000000000331","volume":"35","author":"SR Brix","year":"2024","unstructured":"Brix, S. R. The challenge of assessing remission and relapse in ANCA kidney disease. J. Am. Soc. Nephrol. 35, 395\u2013397 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"75755_CR26","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 68, 1827\u20131832 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"75755_CR27","doi-asserted-by":"publisher","unstructured":"Renson, T. et al. Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a systematic review. RMD Open 10 https:\/\/doi.org\/10.1136\/rmdopen-2023-003579 (2024).","DOI":"10.1136\/rmdopen-2023-003579"},{"key":"75755_CR28","doi-asserted-by":"publisher","first-page":"1254948","DOI":"10.3389\/fimmu.2023.1254948","volume":"14","author":"TB Bennike","year":"2023","unstructured":"Bennike, T. B. Advances in proteomics: characterization of the innate immune system after birth and during inflammation. Front Immunol. 14, 1254948 (2023).","journal-title":"Front Immunol."},{"key":"75755_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-025-11537-6","volume":"26","author":"M Zhang","year":"2025","unstructured":"Zhang, M. et al. Immune status assessment based on plasma proteomics with meta graph convolutional networks. BMC Genomics 26, 360 (2025).","journal-title":"BMC Genomics"},{"key":"75755_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","volume":"2","author":"PE Geyer","year":"2016","unstructured":"Geyer, P. E. et al. Plasma proteome profiling to assess human health and disease. Cell Syst. 2, 185\u2013195 (2016).","journal-title":"Cell Syst."},{"key":"75755_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nmeth.2309","volume":"10","author":"MA Gillette","year":"2013","unstructured":"Gillette, M. A. & Carr, S. A. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 10, 28\u201334 (2013).","journal-title":"Nat. Methods"},{"key":"75755_CR32","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.eclinm.2022.101495","volume":"49","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. EClinicalMedicine 49, 101495 (2022).","journal-title":"EClinicalMedicine"},{"key":"75755_CR33","doi-asserted-by":"publisher","first-page":"e2200018","DOI":"10.1002\/prca.202200018","volume":"17","author":"F Qureshi","year":"2023","unstructured":"Qureshi, F. et al. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteom. Clin. Appl 17, e2200018 (2023).","journal-title":"Proteom. Clin. Appl"},{"key":"75755_CR34","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","volume":"60","author":"S Moiseev","year":"2021","unstructured":"Moiseev, S. et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatol. (Oxf.) 60, 4654\u20134661 (2021).","journal-title":"Rheumatol. (Oxf.)"},{"key":"75755_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J., Bekker, P. & Group, A. S. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med"},{"key":"75755_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1681\/ASN.2008050497","volume":"20","author":"A Schreiber","year":"2009","unstructured":"Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289\u2013298 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"75755_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med Decis. Mak. 26, 565\u2013574 (2006).","journal-title":"Med Decis. Mak."},{"key":"75755_CR38","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons, K. G. et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann. Intern Med 162, W1\u2013W73 (2015).","journal-title":"Ann. Intern Med"},{"key":"75755_CR39","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","volume":"72","author":"PA Monach","year":"2013","unstructured":"Monach, P. A. et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann. Rheum. Dis. 72, 1342\u20131350 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"75755_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13075-017-1429-3","volume":"19","author":"J Ishizaki","year":"2017","unstructured":"Ishizaki, J. et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 19, 218 (2017).","journal-title":"Arthritis Res Ther."},{"key":"75755_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/BMI.S645","volume":"4","author":"S Tseng","year":"2009","unstructured":"Tseng, S., Reddi, A. H. & Di Cesare, P. E. Cartilage oligomeric matrix protein (COMP): a biomarker of arthritis. Biomark. Insights 4, 33\u201344 (2009).","journal-title":"Biomark. Insights"},{"key":"75755_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.matbio.2024.12.005","volume":"135","author":"R de Groot","year":"2025","unstructured":"de Groot, R. et al. Cleavage of Cartilage Oligomeric Matrix Protein (COMP) by ADAMTS4 generates a neoepitope associated with osteoarthritis and other forms of degenerative joint disease. Matrix Biol. 135, 106\u2013124 (2025).","journal-title":"Matrix Biol."},{"key":"75755_CR43","doi-asserted-by":"publisher","unstructured":"Smith, M. M. & Melrose, J. COMP is a biomarker of cartilage destruction, extracellular matrix and vascular remodeling and tissue repair. Int. J. Mol. Sci. 26 https:\/\/doi.org\/10.3390\/ijms26189182 (2025).","DOI":"10.3390\/ijms26189182"},{"key":"75755_CR44","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/art.43110","volume":"77","author":"RT Maughan","year":"2025","unstructured":"Maughan, R. T. et al. Proteomic profiling of the large-vessel vasculitis spectrum identifying shared signatures of innate immune activation and stromal remodeling. Arthritis Rheumatol. 77, 884\u2013900 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"75755_CR45","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2215\/CJN.07210520","volume":"15","author":"JP Aendekerk","year":"2020","unstructured":"Aendekerk, J. P. et al. Urinary Soluble CD163 and disease activity in biopsy-proven ANCA-associated glomerulonephritis. Clin. J. Am. Soc. Nephrol. 15, 1740\u20131748 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"75755_CR46","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1681\/ASN.2021030382","volume":"32","author":"SM Moran","year":"2021","unstructured":"Moran, S. M. et al. The clinical application of urine soluble CD163 in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 32, 2920\u20132932 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"75755_CR47","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ekir.2023.01.013","volume":"8","author":"J Sonnemann","year":"2023","unstructured":"Sonnemann, J. et al. Urinary T cells identify renal antineutrophil cytoplasmic antibody-associated vasculitis and predict prognosis: a proof of concept study. Kidney Int Rep. 8, 871\u2013883 (2023).","journal-title":"Kidney Int Rep."},{"key":"75755_CR48","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","volume":"19","author":"FW Tam","year":"2004","unstructured":"Tam, F. W. et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol. Dial. Transpl. 19, 2761\u20132768 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"75755_CR49","doi-asserted-by":"publisher","unstructured":"Ebert, M. et al. Protective alpha1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation. J. Clin. Invest. 132 https:\/\/doi.org\/10.1172\/JCI160089 (2022).","DOI":"10.1172\/JCI160089"},{"key":"75755_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C. et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"75755_CR51","doi-asserted-by":"publisher","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J 62 https:\/\/doi.org\/10.1183\/13993003.02153-2022 (2023).","DOI":"10.1183\/13993003.02153-2022"},{"key":"75755_CR52","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968 (2010).","journal-title":"Bioinformatics"},{"key":"75755_CR53","first-page":"1","volume":"19","author":"T Valikangas","year":"2018","unstructured":"Valikangas, T., Suomi, T. & Elo, L. L. A systematic evaluation of normalization methods in quantitative label-free proteomics. Brief. Bioinform 19, 1\u201311 (2018).","journal-title":"Brief. Bioinform"},{"key":"75755_CR54","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191\u2013W198 (2019).","journal-title":"Nucleic Acids Res."},{"key":"75755_CR55","doi-asserted-by":"publisher","first-page":"e21800","DOI":"10.1371\/journal.pone.0021800","volume":"6","author":"F Supek","year":"2011","unstructured":"Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 6, e21800 (2011).","journal-title":"PLoS One"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75755-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:02:38Z","timestamp":1784649758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75755"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75755-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.J., M.K., TUBP.B., S.F., P.M., and R.K are inventors on a European patent application submitted by Charit\u00e9 and MDC that covers the work published herein. All other authors declare that they have no further competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6825"}}